Type and hit ENTER

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing client list of pharmaceutical companies and academic laboratories.

ProAxsis specialises in four key areas of business:

ProteaseTag®
Active Neutrophil Elastase Immunoassay
  • Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.
NEATstik®
Neutrophil Elastase Airways Test
  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.
Clinical research services
services for both academic and pharmaceutical company researchers
  • Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.
R&D Projects
are supported by a variety of external partners
  • ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

ProteaseTag® immunoassay - Activity-based immunoassay kits

Activity-based immunoassay kits – Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.

Rapid point-of-care tests – NEATstik®

Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.

Activity-based immunoassay kits

Activity-based immunoassay kits – Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.

Rapid point-of-care tests – NEATstik®

Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.

Clinical research services

Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.

R&D Projects

ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

Welcome to ProAxsis

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease, using its patented ProteaseTag® technology.

ProAxsis specialises in four key areas of business:-

  • Activity-based immunoassay kits – Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.

 

  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.

 

  • Clinical research services – Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.

 

  • R&D Projects – ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners.  We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it has entered into an exclusive licensing agreement with the global biopharmaceutical company AstraZeneca. ProAxsis will take responsibility for completing the validation and global commercialisation of a SARS-CoV-2 (the virus associated with COVID-19) serology ELISA …

June 7, 2021

Introduction In parallel with the release of the company’s 2020 financial statements, I am pleased to provide an associated update on the positive transformation achieved by the company in the previous 12-month period. ProAxsis is a growing Health and Life Sciences company with a primary focus on …

May 21, 2021

ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of Geneva and the University Hospital of Geneva, today announce that they have reached agreement on a global licensing agreement.  Researchers at the University have developed a highly novel assay for a Cathepsin K-dependent periostin …

February 21, 2021
GET CONNECTED
RECENT POSTS
ABOUT ME
LIFESTYLE
SHOP ONLINE
old Home | ProAxsis